<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01262131</url>
  </required_header>
  <id_info>
    <org_study_id>10242-01</org_study_id>
    <nct_id>NCT01262131</nct_id>
  </id_info>
  <brief_title>Evaluation of Magnetic Fields to Treat Fibromyalgia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Fibromyalgia: Pilot Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pico-tesla Magnetic Therapies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>pico-tesla Magnetic Therapies, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a device called the Resonator can help to reduce pain
      and improve aspects of health and quality of life for people with fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to assess the efficacy of the Resonator device as an
      adjunctive therapy to reducing pain and improving aspects of health and quality of life that
      are relevant to individuals with fibromyalgia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.</measure>
    <time_frame>2 weeks (baseline to end of treatment)</time_frame>
    <description>Minimum scale value is '0' which represents 'no pain at all' and is the best outcome.
Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Resonator Protocol A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Resonator Protocol B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of magnetic fields using the Resonator device Protocol B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive Resonator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>magnetic therapy protocol A</intervention_name>
    <description>Application of magnetic fields using the Resonator device Protocol A</description>
    <arm_group_label>Resonator Protocol A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>magnetic therapy Protocol B</intervention_name>
    <description>Application of magnetic fields using the Resonator device Protocol B</description>
    <arm_group_label>Resonator Protocol B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo therapy</intervention_name>
    <description>Application of inactive magnetic fields using the Resonator device</description>
    <arm_group_label>Inactive Resonator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current diagnosis of fibromyalgia made by the study Principal Investigator (PI)
             according to the American College of Rheumatology 1990 Criteria for the Classification
             of Fibromyalgia.

          -  Rating of current Degree of Pain on the 0-10 Numeric Pain Intensity Scale of 4 or
             greater.

          -  Subject's use of pain relief medication(s) has been stable over the past 30 days, and
             subject is willing and able to maintain pre-existing use of pain relief medication(s)
             as his or her sole pain relief medication use, as needed, throughout study
             participation.

          -  Subject's use of insomnia medication(s) has been stable over the past 30 days, and
             subject is willing and able to maintain this existing use of insomnia medication(s) as
             his or her sole insomnia relief medication(s), as needed, throughout study
             participation.

          -  Subject has been on current (or no) medication regimen, unchanged for at least 30 days
             prior to study enrollment, and is willing and able to maintain that regular medication
             regimen, unchanged, throughout study participation.

          -  Willing and able to refrain from use of tender point injections throughout study
             participation.

          -  Willing and able to abstain from partaking in other/new treatments to improve
             fibromyalgia symptoms during study participation.

          -  Adequate contraceptive measures for female subjects.

          -  18 years of age or older.

          -  Male or female.

        Exclusion Criteria:

          -  Any factors that might prevent the subject from completing a full course of therapy
             with the Resonatorâ„¢ device, or from attending any of the scheduled study visits, or
             from completing any of the study measures.

          -  Subject suffers from co-existent chronic pain condition(s) of non-fibromyalgia origin,
             such as osteoarthritis, low back pain, neck pain, painful diabetic neuropathy and
             postherpetic neuropathic pain, that cannot be distinguished in severity and/or in
             type/sensation of pain from the pain originating from the subject's condition of
             fibromyalgia.

          -  Any other significant comorbidities that might impact the ability to evaluate the
             subject's satisfaction of the ACR 1990 Criteria for the Classification of
             Fibromyalgia, or for the subject to complete any of the study assessment tools.

          -  Tender point injections received within the prior one month.

          -  Current or past history of major psychiatric disturbance (e.g., schizophrenia, bipolar
             disorder, substance abuse).

          -  Known inflammatory rheumatic disease.

          -  Epilepsy/history of seizures/taking medication for epilepsy.

          -  HIV and other autoimmune disorders.

          -  Active cancer or treatment for cancer within last 6 months.

          -  Active infection(s).

          -  History of ECT

          -  Uncontrolled Hypertension.

          -  Advanced Pulmonary Disease.

          -  Unstable cardiac disease.

          -  Prosthetics or implants comprised of ferrous metals.

          -  Pacemakers, vagus nerve stimulators, or other functional electrical stimulators such
             as those commonly used for pain.

          -  Consumption of more than 21 alcoholic drinks per week.

          -  Pregnant, breast feeding, or planning pregnancy prior to end of study participation.

          -  Developmental disability or other cognitive impairment that would in the judgment of
             the PI impair adequate comprehension of the informed consent form or complete any of
             the study-related activities.

          -  Worker's compensation, receipt of disability or present/past litigation for monetary
             compensation pertaining to subject's fibromyalgia condition.

          -  Participation in other research within 30 days of study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry I Jacobson, Ph.D, D.M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>June 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 1, 2011</results_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Allen S. Braswell CEO, pico-tesla Magnetic Therapies, LLC</name_title>
    <organization>Pico-Tesla Magnetic Therapies, LLC</organization>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>Pain associated with Fibromyalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Resonator Protocol A</title>
          <description>Application of magnetic fields using the Resonator device protocol A</description>
        </group>
        <group group_id="P2">
          <title>Resonator Protocol B</title>
          <description>Application of magnetic fields using the Resonator device treatment protocol B</description>
        </group>
        <group group_id="P3">
          <title>Inactive Resonator</title>
          <description>Application of inactive magnetic fields using the Resonator device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Resonator Protocol A</title>
          <description>Application of magnetic fields using the Resonator device protocol A</description>
        </group>
        <group group_id="B2">
          <title>Resonator Protocol B</title>
          <description>Application of magnetic fields using the Resonator device treatment protocol B</description>
        </group>
        <group group_id="B3">
          <title>Inactive Resonator</title>
          <description>Application of inactive magnetic fields using the Resonator device</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.</title>
        <description>Minimum scale value is '0' which represents 'no pain at all' and is the best outcome.
Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome.</description>
        <time_frame>2 weeks (baseline to end of treatment)</time_frame>
        <population>Analysis was by intention to treat which included all enrolled subjects in this case to study completion.</population>
        <group_list>
          <group group_id="O1">
            <title>Resonator Protocol A</title>
            <description>Application of magnetic fields using the Resonator device protocol A</description>
          </group>
          <group group_id="O2">
            <title>Resonator Protocol B</title>
            <description>Application of magnetic fields using the Resonator device treatment protocol B</description>
          </group>
          <group group_id="O3">
            <title>Inactive Resonator</title>
            <description>Application of inactive magnetic fields using the Resonator device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.</title>
          <description>Minimum scale value is '0' which represents 'no pain at all' and is the best outcome.
Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome.</description>
          <population>Analysis was by intention to treat which included all enrolled subjects in this case to study completion.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.69" spread="1.2"/>
                    <measurement group_id="O2" value="-3.08" spread="1.2"/>
                    <measurement group_id="O3" value="-1.97" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Resonator Protocol A</title>
          <description>Application of magnetic fields using the Resonator device protocol A</description>
        </group>
        <group group_id="E2">
          <title>Resonator Protocol B</title>
          <description>Application of magnetic fields using the Resonator device treatment protocol B</description>
        </group>
        <group group_id="E3">
          <title>Inactive Resonator</title>
          <description>Application of inactive magnetic fields using the Resonator device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allen S. Braswell CEO</name_or_title>
      <organization>Pico-Tesla Magnetic Therapies, LLC</organization>
      <phone>303 795-3222</phone>
      <email>abraswell@pico-tesla.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

